242 related articles for article (PubMed ID: 33121133)
21. Botulinum Toxin Type A Injection for Cervical Dystonia in Adults with Dyskinetic Cerebral Palsy.
Yi YG; Kim K; Yi Y; Choi YA; Leigh JH; Bang MS
Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29772695
[TBL] [Abstract][Full Text] [Related]
22. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance.
Samotus O; Lee J; Jog M
J Neurol; 2018 Jun; 265(6):1269-1278. PubMed ID: 29557988
[TBL] [Abstract][Full Text] [Related]
23. Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study.
Colosimo C; Charles D; Misra VP; Maisonobe P; Om S;
J Neurol Sci; 2020 Sep; 416():117015. PubMed ID: 32682125
[TBL] [Abstract][Full Text] [Related]
24. RimabotulinumtoxinB effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studies.
Lew MF; Chinnapongse R; Zhang Y; Corliss M
Int J Neurosci; 2010 Apr; 120(4):298-300. PubMed ID: 20374078
[TBL] [Abstract][Full Text] [Related]
25. Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study.
Patel AT; Lew MF; Dashtipour K; Isaacson S; Hauser RA; Ondo W; Maisonobe P; Wietek S; Rubin B; Brashear A
PLoS One; 2021; 16(2):e0245827. PubMed ID: 33524060
[TBL] [Abstract][Full Text] [Related]
26. Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia.
Berman B; Seeberger L; Kumar R
Mov Disord; 2005 Feb; 20(2):233-7. PubMed ID: 15455449
[TBL] [Abstract][Full Text] [Related]
27. Botulinum toxin type A and cervical dystonia: a seven-year follow-up.
Camargo CH; Teive HA; Becker N; Munhoz RP; Werneck LC
Arq Neuropsiquiatr; 2011 Oct; 69(5):745-50. PubMed ID: 22042174
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
Factor SA; Molho ES; Evans S; Feustel PJ
Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
[TBL] [Abstract][Full Text] [Related]
29. Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes.
Jinnah HA; Goodmann E; Rosen AR; Evatt M; Freeman A; Factor S
J Neurol; 2016 Jun; 263(6):1188-94. PubMed ID: 27113604
[TBL] [Abstract][Full Text] [Related]
30. "Pseudo"-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study.
Hefter H; Rosenthal D; Samadzadeh S
Toxins (Basel); 2023 Oct; 15(10):. PubMed ID: 37888649
[TBL] [Abstract][Full Text] [Related]
31. A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia.
Hu W; Rundle-Gonzalez V; Kulkarni SJ; Martinez-Ramirez D; Almeida L; Okun MS; Wagle Shukla A
Parkinsonism Relat Disord; 2019 Jun; 63():195-198. PubMed ID: 30837195
[TBL] [Abstract][Full Text] [Related]
32. The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia.
Samadzadeh S; Brauns R; Hefter H
Toxins (Basel); 2020 Dec; 13(1):. PubMed ID: 33396548
[TBL] [Abstract][Full Text] [Related]
33. Treatment of cervical dystonia with botulinum toxins.
Comella CL; Thompson PD
Eur J Neurol; 2006 Feb; 13 Suppl 1():16-20. PubMed ID: 16417593
[TBL] [Abstract][Full Text] [Related]
34. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Simpson DM; Hallett M; Ashman EJ; Comella CL; Green MW; Gronseth GS; Armstrong MJ; Gloss D; Potrebic S; Jankovic J; Karp BP; Naumann M; So YT; Yablon SA
Neurology; 2016 May; 86(19):1818-26. PubMed ID: 27164716
[TBL] [Abstract][Full Text] [Related]
35. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin.
Marion MH; Humberstone M; Grunewald R; Wimalaratna S
Pract Neurol; 2016 Aug; 16(4):288-95. PubMed ID: 26976927
[TBL] [Abstract][Full Text] [Related]
36. Targeting pain in the long-term treatment of cervical dystonia with botulinum toxin A.
Marciniec M; Szczepańska-Szerej A; Papuć E; Rejdak K
Int J Neurosci; 2022 Oct; 132(10):1026-1030. PubMed ID: 33295845
[TBL] [Abstract][Full Text] [Related]
37. Outcome of selective ramisectomy for botulinum toxin resistant torticollis.
Ford B; Louis ED; Greene P; Fahn S
J Neurol Neurosurg Psychiatry; 1998 Oct; 65(4):472-8. PubMed ID: 9771768
[TBL] [Abstract][Full Text] [Related]
38. INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin.
Misra VP; Colosimo C; Charles D; Chung TM; Maisonobe P; Om S;
J Neurol; 2018 Feb; 265(2):402-409. PubMed ID: 29270685
[TBL] [Abstract][Full Text] [Related]
39. Exploring the Interplay between the Clinical and Presumed Effect of Botulinum Injections for Cervical Dystonia: A Pilot Study.
Hefter H; Samadzadeh S
Toxins (Basel); 2023 Sep; 15(10):. PubMed ID: 37888623
[TBL] [Abstract][Full Text] [Related]
40. The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia.
Hefter H; Ürer B; Brauns R; Rosenthal D; Meuth SG; Lee JI; Albrecht P; Samadzadeh S
J Neurol; 2022 Nov; 269(11):5991-6002. PubMed ID: 35842881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
